US11191802B2 - Composition for controlled release of therapeutic agents - Google Patents

Composition for controlled release of therapeutic agents Download PDF

Info

Publication number
US11191802B2
US11191802B2 US16/376,930 US201916376930A US11191802B2 US 11191802 B2 US11191802 B2 US 11191802B2 US 201916376930 A US201916376930 A US 201916376930A US 11191802 B2 US11191802 B2 US 11191802B2
Authority
US
United States
Prior art keywords
amino acids
peptide
seq
independently
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/376,930
Other languages
English (en)
Other versions
US20190307834A1 (en
Inventor
Michael M. Sekar
Manish Singhal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amma Therapeutics Inc
Original Assignee
Amma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amma Therapeutics Inc filed Critical Amma Therapeutics Inc
Priority to US16/376,930 priority Critical patent/US11191802B2/en
Assigned to AMMA Therapeutics, Inc. reassignment AMMA Therapeutics, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SEKAR, MICHAEL M., SINGHAL, MANISH
Publication of US20190307834A1 publication Critical patent/US20190307834A1/en
Priority to US17/519,378 priority patent/US20220202896A1/en
Application granted granted Critical
Publication of US11191802B2 publication Critical patent/US11191802B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US16/376,930 2018-04-06 2019-04-05 Composition for controlled release of therapeutic agents Active US11191802B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/376,930 US11191802B2 (en) 2018-04-06 2019-04-05 Composition for controlled release of therapeutic agents
US17/519,378 US20220202896A1 (en) 2018-04-06 2021-11-04 Composition for controlled release of therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653951P 2018-04-06 2018-04-06
US16/376,930 US11191802B2 (en) 2018-04-06 2019-04-05 Composition for controlled release of therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/519,378 Continuation US20220202896A1 (en) 2018-04-06 2021-11-04 Composition for controlled release of therapeutic agents

Publications (2)

Publication Number Publication Date
US20190307834A1 US20190307834A1 (en) 2019-10-10
US11191802B2 true US11191802B2 (en) 2021-12-07

Family

ID=68096259

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/376,930 Active US11191802B2 (en) 2018-04-06 2019-04-05 Composition for controlled release of therapeutic agents
US17/519,378 Abandoned US20220202896A1 (en) 2018-04-06 2021-11-04 Composition for controlled release of therapeutic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/519,378 Abandoned US20220202896A1 (en) 2018-04-06 2021-11-04 Composition for controlled release of therapeutic agents

Country Status (6)

Country Link
US (2) US11191802B2 (de)
EP (1) EP3773483A4 (de)
JP (1) JP2021521270A (de)
KR (1) KR20200140291A (de)
CN (1) CN112074287A (de)
WO (1) WO2019195766A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220202896A1 (en) * 2018-04-06 2022-06-30 AMMA Therapeutics, Inc. Composition for controlled release of therapeutic agents

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110615829B (zh) * 2019-09-29 2022-07-19 深圳市三浦天然化妆品有限公司 一种自组装抗菌肽水凝胶

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675381A (en) 1983-07-01 1987-06-23 Battelle Memorial Institute Biodegradable polypeptide and its use for the gradual release of drugs
WO2001047549A2 (en) 1999-12-23 2001-07-05 University College London Conjugate useful as building block for vaccine preparation
WO2004043432A2 (en) 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
US20110311594A1 (en) 2010-06-22 2011-12-22 Shou-Chiung Chen Controlled release compositions with reduced food effect
WO2012131106A1 (en) 2011-03-31 2012-10-04 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022735A1 (en) * 2002-08-02 2004-02-05 Uzgiris Egidijus E Enzyme activated contrast agents
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
US8389481B2 (en) * 2008-11-12 2013-03-05 University Of Medicine And Dentistry Of New Jersey Glutamate-enhanced cell-penetrating peptides and methods of using same
AU2012298824B2 (en) * 2011-08-23 2017-06-01 President And Fellows Of Harvard College Peptide nanoparticles and uses thereof
CN103788211B (zh) * 2012-11-01 2017-09-01 中国科学院上海药物研究所 双功能肽、所述双功能肽与核酸分子形成的复合物以及治疗肿瘤的药物组合物
US20170202783A1 (en) * 2014-07-08 2017-07-20 Northeastern University Amphiphilic Peptide Nanoparticles for Use as Hydrophobic Drug Carriers and Antibacterial Agents
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
EP3773483A4 (de) * 2018-04-06 2022-01-26 Amma Therapeutics, Inc. Zusammensetzung zur kontrollierten freisetzung von therapeutika

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675381A (en) 1983-07-01 1987-06-23 Battelle Memorial Institute Biodegradable polypeptide and its use for the gradual release of drugs
WO2001047549A2 (en) 1999-12-23 2001-07-05 University College London Conjugate useful as building block for vaccine preparation
WO2004043432A2 (en) 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
US20110311594A1 (en) 2010-06-22 2011-12-22 Shou-Chiung Chen Controlled release compositions with reduced food effect
WO2012131106A1 (en) 2011-03-31 2012-10-04 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
International Search Report and Written Opinion for PCT/US2019/026120 dated Sep. 12, 2019, 12 pages.
Panda et al., "Self-assembled nanoparticles based on modified cationic dipeptides and DNA: novel systems for gene delivery", Journal of Nanobiotechnology, Jun. 21, 2013, vol. 11, pp. 1-13.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220202896A1 (en) * 2018-04-06 2022-06-30 AMMA Therapeutics, Inc. Composition for controlled release of therapeutic agents

Also Published As

Publication number Publication date
EP3773483A1 (de) 2021-02-17
US20220202896A1 (en) 2022-06-30
WO2019195766A1 (en) 2019-10-10
EP3773483A4 (de) 2022-01-26
US20190307834A1 (en) 2019-10-10
KR20200140291A (ko) 2020-12-15
CN112074287A (zh) 2020-12-11
JP2021521270A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
AU2016201819B2 (en) Biodegradable drug delivery composition
US20220202896A1 (en) Composition for controlled release of therapeutic agents
US20240150426A1 (en) Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US20230165964A1 (en) Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
US20220378931A1 (en) Insulin analogs and methods of using the same
US20210128598A1 (en) Radiation-Sterilized Biodegradable Drug Delivery Compositions
US20240156897A1 (en) Composition for controlled release of therapeutic agents
US20180251495A1 (en) Skin-Penetrating Peptides and Compositions and Methods of Use Thereof
WO2016033314A1 (en) Skin penetrating peptides (spps) and methods of use therefor

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: AMMA THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SEKAR, MICHAEL M.;SINGHAL, MANISH;REEL/FRAME:049796/0172

Effective date: 20190624

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE